US009408905B2

(12) **United States Patent**
Yao

(10) **Patent No.: US 9,408,905 B2**
(45) **Date of Patent: *Aug. 9, 2016**

(54) **HERPES SIMPLEX VIRUS VACCINES**

(71) Applicant: **THE BRIGHAM AND WOMEN'S HOSPITAL, INC.**, Boston, MA (US)

(72) Inventor: **Feng Yao**, Needham, MA (US)

(73) Assignee: **THE BRIGHAM AND WOMEN'S HOSPITAL, INC.**, Boston, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/320,923**

(22) Filed: **Jul. 1, 2014**

(65) **Prior Publication Data**

US 2014/0314811 A1 Oct. 23, 2014

Related U.S. Application Data

(63) Continuation of application No. 13/517,232, filed as application No. PCT/US2010/061320 on Dec. 20, 2010, now Pat. No. 8,809,047.

(60) Provisional application No. 61/288,836, filed on Dec. 21, 2009.

(51) **Int. Cl.**

A61K 39/245	(2006.01)
A61K 39/12	(2006.01)
C12N 7/00	(2006.01)
A61K 39/00	(2006.01)
A61K 35/76	(2015.01)
A61K 35/763	(2015.01)
G01N 33/569	(2006.01)
C12N 15/869	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 39/245*** (2013.01); ***A61K 39/12*** (2013.01); ***C12N 7/00*** (2013.01); *A61K 35/763* (2013.01); *A61K 2039/5254* (2013.01); *A61K 2039/5256* (2013.01); *A61K 2039/545* (2013.01); *A61K 2039/57* (2013.01); *C12N 15/869* (2013.01); *C12N 15/8695* (2013.01); *C12N 2710/16011* (2013.01); *C12N 2710/16034* (2013.01); *C12N 2710/16611* (2013.01); *C12N 2710/16621* (2013.01); *C12N 2710/16634* (2013.01); *C12N 2710/16661* (2013.01); *G01N 33/56994* (2013.01)

(58) **Field of Classification Search**

CPC C12N 15/86; C12N 2710/16643; C12N 7/00; C12N 2710/16622; C12N 15/111; C12N 2710/16043; C12N 15/8695; A61K 35/763; A61K 39/245; A61K 38/2086; C07K 14/005; C07K 14/035

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,464,758	A	11/1995	Gossen	
5,589,362	A	12/1996	Bujard	
5,763,217	A	6/1998	Cynader et al.	
5,770,414	A	6/1998	Gage et al.	
5,917,122	A	6/1999	Byrne	
5,965,440	A	10/1999	Reeves	
5,972,650	A	10/1999	Yao	
6,027,730	A	2/2000	Francotte et al.	
6,183,753	B1	2/2001	Cochran et al.	
6,251,640	B1	6/2001	Yao	
6,261,552	B1	7/2001	De Luca	
6,444,871	B1	9/2002	Yao	
6,635,478	B1	10/2003	Hippenmeyer et al.	
6,846,670	B2	1/2005	Schwartz et al.	
7,223,411	B1	5/2007	Knipe et al.	
8,236,941	B2	8/2012	Yao	
2002/0028484	A1	3/2002	Yao	
2003/0113348	A1	6/2003	Coffin	
2003/0165537	A1	9/2003	Fehler et al.	
2004/0029229	A1	2/2004	Reeves et al.	
2004/0063094	A1	4/2004	Coffin	
2004/0229362	A1	11/2004	Epstein et al.	
2005/0266564	A1	12/2005	Yao	
2006/0116340	A1	6/2006	Lewin	
2008/0008686	A1	1/2008	Yao	
2008/0299140	A1*	12/2008	Georges	A61K 39/245 424/186.1
2010/0015687	A1	1/2010	Yao	
2012/0190106	A1	7/2012	Yao	

FOREIGN PATENT DOCUMENTS

CN	1065997	A	11/1992
CN	1503843	A	6/2004
WO	WO 94/04672		3/1994
WO	2004029258		4/2004
WO	WO 2011/025717	A2	3/2011
WO	2011079073	A2	6/2011

OTHER PUBLICATIONS

Preston CM, Nicholl MJ. Repression of gene expression upon infection of cells with herpes simplex virus type 1 mutants impaired for immediate-early protein synthesis. J Virol. Oct. 1997;71(10):7807-13.*

Lu Z, Brans R, Akhrameyeva NV, Murakami N, Xu X, Yao F. High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection. J Invest Dermatol. May 2009;129(5):1174-84. Epub Nov. 13, 2008.*

McGeoch DJ. UL9 [Human herpesvirus 1]. GenBank Acc. No: CAA32345.1. Dep. Oct. 23, 2008.*

Armentano, et al., E4ORF3 Requirement for Achieving Long-Term Transgene Expression from the Cytomegalovirus Promoter in Adenovirus Vectors, Journal of Virology, vol. 73, pp. 7031-7034, 1999.

(Continued)

Primary Examiner — Rachel B Gill

(74) *Attorney, Agent, or Firm* — Nixon Peabody LLP

(57) **ABSTRACT**

The present invention is directed to Herpes simplex-2 viruses that may be used in vaccines to immunize patients against genital herpes.

30 Claims, 6 Drawing Sheets